Healthcare / Medical Instruments & SuppliesStockholm
$2.34
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-20.1M · quality 57.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$207M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-97.6%
↓Gross Margin
40.3%
↓Debt/Equity
0.87
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.1%
FCF CAGR
—
FCF margin
-47.5%
FCF / Net income
1.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $73.4M · net income $-21.9M · FCF $-34.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $73.4M | $73.4M | $80.4M | $84.1M | $104.5M |
| Net Income | $-21.9M | $-21.9M | $-24.9M | $-18.2M | $5.9M |
| EBITDA | $-14.7M | $-14.7M | $-15.7M | $-14.9M | $8.3M |
| EPS | -0.43 | -0.43 | -0.56 | -0.41 | 0.13 |
| Gross Margin | 40.3% | 40.3% | 34.7% | 36.7% | 46.6% |
| Operating Margin | -19.4% | -19.4% | -23.7% | -19.5% | 6.4% |
| Net Margin | -29.8% | -29.8% | -31.0% | -21.7% | 5.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.87 | 0.87 | -5.31 | 0.32 | 0.17 |
| Current Ratio | 1.21 | 1.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-34.8M | $-34.8M | $-20.1M | $-11.1M | $-13.0M |
| Returns | |||||
| ROE | -97.6% | -97.6% | 347.6% | -105.4% | 16.6% |
| Valuation | |||||
| P/E | — | — | — | — | 50.00 |
| EV/EBITDA | — | — | — | — | 34.39 |
| P/B | 5.37 | 5.37 | — | 14.98 | 8.13 |
| Growth & Yield | |||||
| Revenue Growth | -8.7% | -8.7% | -4.4% | -19.5% | — |
| EPS Growth | 23.2% | 23.2% | -36.6% | -415.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-19.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.56 → -0.43
Residual
-19.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.